the SYNERGISTIC approach
Age-related anatomical changes are most effectively managed through the combination of science and technology. To achieve this goal, Neauvia’s research designed SMART COMBINATION THERAPY, which combines different restorative therapies and grants clinically proven superior results. 1, 2, 3
who we are
Created in 2012, Neauvia is distributed in more than 80 countries worldwide. Today, it stands as a high-growth multinational corporation with production sites and subsidiaries in Italy, Switzerland, France, Spain, Poland, Germany, the UK and the US.
Neauvia offers clinically proven combined solutions for healthcare practitioners and patients.
Part of the MatexLab Group, which is backed by leading central European private equity firm Abris Capital, Neauvia is a pioneer in medical aesthetics and has developed ground-breaking synergistic smart combination therapies.
#Be
INDEPENDENT
#Be
DYNAMIC
#Be
FOCUSED
#Be
PASSIONATE
products portfolio
Pioneer with PEG
Neauvia chose PEG differentiating itself in the market. PEG is a well-known polymer in the pharmaceutical market, due to its uniqueness, versatility and safety profile 4, 5.
Neauvia PEG-HA Fillers are based on a unique patented Smart Crosslinking Technology (SXT) which is an innovative and advanced technology that combines Hyaluronic Acid and PEGDE in one network.
NEAUVIA SCIENTIFIC ACADEMY has been created to provide highest quality medical education by supporting healthcare professionals in the development of their practice and skills for better patients’ outcomes. One of the main objectives of the NEAUVIA SCIENTIFIC ACADEMY is to strengthen medical knowledge from product research to the effective use in daily practice.
latest news
Neauvia APAC Summit
Deep dive into the Neauvia APAC Summit in Bangkok!
Read more
- Kubik P, Jankau J, Rauso R, Galadari H, Protasoni M, Gruszczyński W, Grzanka D, Smolińska M, Antosik P, Piesiaków ML, Zerbinati N et al. HA PEGylated filler in association with an infrared energy device for the treatment of facial skin aging: 150 day follow-up data report. Pharmaceuticals 2022, 15, 1355. https://doi.org/10.3390/ph15111355
- Kolczewski P, Parafiniuk M, Zawodny P, Haddad R, Nalewczyńska A, Kolasa AK, Wiszniewska B, Menkes S, Bader A, Stabile G and Zerbinati N. Hyaluronic Acid and radiofrequency in patients with urogenital atrophy and vaginal laxity. Pharmaceuticals 2022, 15, 1571. https://doi.org/10.3390/ph15121571
- Płatkowska A, Korzekwa S, Łukasik B and Zerbinati N. combined bipolar radiofrequency and non-crosslinked Hyaluronic Acid mesotherapy protocol to improve skin appearance and epidermal barrier function: a pilot study. Pharmaceuticals 2023, 16, 1145. https://doi.org/10.3390/ph16081145
- Marino F, Cosentino M, Legnaro M, Luini A, Sigova J, Mocchi R, Lotti T and Zerbinati N. Immune profile of Hyaluronic Acid hydrogel Polyethylene Glycol crosslinked: an in vitro evaluation in human polymorphonuclear leukocytes. Dermatologic Therapy. 2020; e13388. https://doi.org/10.1111/dth.1338
- Jeong CH, Kim DH, Yune JH, Kwon HC, Shin DM, Sohn H, Lee KH, Choi B, Kim ES, Kang JH, Kim EK and Han SG. In vitro toxicity assessment of crosslinking agents used in Hyaluronic Acid dermal filler. Toxicology in Vitro, Volume 70, 2021, 105034, ISSN 0887-2333. https://doi.org/10.1016/j.tiv.2020.105034